A new generation eczema drug used to treat adults has just been approved for use in Australian teenagers. Dupilumab, which is sold as Dupixent, was approved in Australia for use in adults in 2018, but further studies were carried out to check its safety and efficacy in teens with the debilitating skin condition. The Therapeutic Goods Administration has now approved the drug for use in 12 to 17-year-olds with moderate to severe eczema. A new generation eczema drug used to treat adults has just been approved for use in Australian teenagers. (9News) Eczema is caused by an overactive immune system. While it is sometimes dismissed as an itchy rash, it can have a profound effect on sufferers. Some children with eczema grow out of it but once it continues into adolescent years, sustained treatment is often necessary. Professor Connie Katelaris, Head of Immunology and Allergy at Campbelltown Hospital, says […]